In reply to@JdmoneyThey are behind that schedule, and there's...

In reply to@Jdmoney

They are behind that schedule, and there's obviously a fair level of positive results already captured in the SP, but this comment seems to have been glossed over:

"It is important to note that participants who exhibited strong efficacy data in previous cohorts experienced the maximum effect several months after receiving 67Cu-SAR-bisPSMA (in some cases, almost 5 months after receiving one single dose of the product)."

So apart from having to wait for the DLT period to expire before subsequent doses and before the next three patients can be enrolled, there may be a reluctance from patients / doctors to rush ahead with doses 3 and 4. If your tumour burden is decreasing, and the maximum effects of earlier doses are only seen several months after dosing, there may be a desire to wait and see, rather than unnecessarily administering more radiation than a patient may need.

I also like the fact that 64Cu-SAR-bisPSMA was used to assess the efficacy of 67Cu-SAR-bisPSMA. Another point that wasn't in the Highlights section of the announcement.

GLTA.